Gastric cancer is the third leading cause of cancer death in both sexes, and high mortality rates are present in Central and Eastern Europe, and in Central and South America. The Latin American and European countries network for precision medicine approach in Gastric Cancer (LEGACy) aims to tailor cancer control to specific patient groups by establishing evidence obtained through international high-quality translational collaborative research. LEGACy aims to design a cost-effective diagnosis algorithm based on the tumour biology knowledge due to identify the high-risk groups in patients diagnosed with stage III and IV gastric cancer and compare the regional differences between Community of Latin American and Caribbean States (CELAC) and EU countries participating in this project. The project will run from December 2018 until December 2022.

 

LEGACy Ambition

 

LEGACy Interventions


ECPC's Role

ECPC will lead Work Package 5 ‘Communication and Dissemination’, which is responsible for a full dissemination, exploitation and communication of all project outreach activities, empowering patients and their families by ensuring new insights are effectively communicated, and a final stakeholder event at the completion of the project. Additionally, ECPC will be contributing to Work Package 3 'Complex data analysis' through the designing of a project website with access to the different data collected for the facilitation of communication between various stakeholders, as well as Work Package 4 'Translation to clinical practice' by providing the patient perspective. ECPC is also part of Work Package 6 ‘Coordination and Management’, responsible for the ethical oversight of the project and ensuring patient-centricity.

 

LEGACy WPs


Contact Points

ECPCIsabelle Manneh-Vangramberen, ECPC Head of Health and Research Programmes


Funding

EU Flag

LEGACy is currently in the Grant Preperation stage for Horizon 2020: the EU Framework Programme for Research and Innovation.